Innovate Biopharmaceuticals, Inc. (INNT) Increased to $24.87

June 29, 2018 - By Margaret Staats

Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) increased significantly to $24.87. Barchart.com reported it on Jun, 29. It has $638.92M MC. The company’s valuation will be $31.95 million more at $26.11 PT.

For more Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) news announced briefly go to: Benzinga.com, Globenewswire.com, Benzinga.com, Globenewswire.com or Nasdaq.com. The titles are as follows: “50 Biggest Movers From Friday” announced on June 25, 2018, “Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of …” on June 13, 2018, “44 Biggest Movers From Yesterday” with a publish date: June 26, 2018, “Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on …” and the last “The 3 Best Biotech Stocks of 2018 So Far” with publication date: June 28, 2018.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics.The firm is worth $638.92 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH).Last it reported negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.